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Abstract
Purpose: We aimed to evaluate its safety in the emergency neurosurgical
population at a tertiary hospital center.
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Ernesto P Molmenti2,
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Rafael Barrera

Methods: Retrospective analyses of prospectively-collected data were performed
on patients ad-mitted to the surgical intensive care unit (SICU) after emergency
neurosurgical procedure. We examined patient demographic and clinical
information, survival outcomes, and rates of heparin induced thrombocytopenia
and pulmonary embolism in patients who received subcutaneous unfractionated
heparin (SCUFH) compared to those who did not. Results: We identified 223
emergency neurosurgical patients, of which 100 received no anticoagulation
(44.84%) and 123 received SCUFH (55.16%). In the SCUFH group, 88 patients
received chemoprophylaxis within 24 h and 35 after 24 h. A statistically significant
difference was noted with the admission APACHE II score of patients receiving
SCUFH to those who did not, but APACHE III and SAPS on admission were shown
to have no difference in outcome.
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Conclusion: Administration of SCUFH in the emergency neurosurgical population
does not increase the risk of bleeding post-operatively and continues to be a safe
and effective chemoprophylaxis agent against VTE.

MD, Department of Surgery and Critical
Care Medicine, Northwell Health System,
Manhasset, USA.

Keywords: Low molecular weight heparin; Subcutaneous unfractionated heparin;
Thromboprophylaxis; Anticoagulation; Dosing; Neurosurgery
Received: February 22, 2017; Accepted: February 26, 2017; Published: February 28,
2017

Introduction
Venous thromboembolism (VTE), including pulmonary embolism
(PE) and deep venous thrombosis (DVT), is a well-described
process that can cause significant morbidity and mortality. This is
especially true in the patient population of a critical care unit [1].
The true incidence of thromboembolic disease in the critically-ill
neurosurgical population admitted to a critical care setting has
not been well described in the literature. In the absence of VTE
thrombo-prophylaxis, the incidence of DVT has been observed
between 10-40% in the general surgery population and as high as
40-60% in the major orthopedic surgery population [2].
In addition to VTE risk, mortality rates have also been stratified
with VTE prophylaxis in mind, and institution of DVT prophylaxis
results in decreased mortality risk [3-5]. Multiple case reports and
series on postoperative thromboembolic prophylaxis have been
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published, however clear guidelines for a “Best Practice” have
yet to be described [6-8]. Many investigators and even whole
institutions have taken to stratifying the risk for developing VTE
and treating the calculated risk accordingly. Treatment modalities
range from encouraging early ambulation in the hospitalized
patient to the use of compression stockings and/or therapeutic
medical management [9].
Despite these ideas and methods, there is a hesitation and
a paucity of data in its use the critically-ill neurosurgical
population. The neurosurgery community has not developed a
unified approach for the prevention of VTE thrombo-prophylaxis
in this population [10]. While there is no doubt that stockings and

© Under License of Creative Commons Attribution 3.0 License | This article is available in: http://criticalcare.imedpub.com/archive.php
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ambulation are effective modalities, these are of-ten not feasible
options for a critically-ill neurosurgical patient. The fear behind
chemoprophylaxis is the risk of causing or worsening a cerebral
or spinal hemorrhage, yet these fears must be balanced with the
morbidity and mortality behind DVT propagation and subsequent
embolic events related to immobility.
Our institution previously published a study examining the
administration of subcutaneous unfractionated heparin
(SCUFH) in 522 neurosurgery patients to determine the risk of
post-operative hemorrhage [11]. We found no embolic events
associated with the use of SCUFH, suggesting that there was no
increased risk of bleeding in the general neurosurgical population.
However, in the emergency neurosurgery setting, where patients
are at high risk of developing VTE, the likelihood of receiving
SCUFH or other forms of prophylaxis are significantly reduced
compared to non-emergency cases [12] possibly related to the
potential bleeding complications. This study is a retrospective
analysis of prospectively-collected data evaluating the efficacy
and safety of SCUFH in patients who underwent emergency
neurosurgical procedures.

Methods
This is a retrospective review of prospectively-acquired data
at a single institution at Long Island Jewish Medical Center. All
patients in this study were admitted to the surgical intensive
care unit and cared for by a dedicated surgical critical care team.
We documented whether patients subcutaneous unfractionated
heparin or not for venous thromboembolism (VTE) prophylaxis.
Stratification of SCUFH was based upon the admitting and/or
operating attending preference after discussion with the SICU
attending. Of the patients receiving SCUFH, we delineated if
patients received SCUFH within 24 h of surgery or greater than
24 h after surgery. All SCUFH patients received 5000 units of
SCUFH every eight h until discharge, and no study patients
were stopped prematurely or changed to low-molecular weight
heparin (LMWH) products. All patients routinely received lower
extremity compression boots; compliance was monitored by the
nursing staff as per hospital policy. The patients were followed
until date of discharge from SICU or death.
Inclusion criteria consisted of all neurosurgical and head trauma
patients who required surgical intervention in the emergency
setting. None of these patients had a history of heparin induced
thrombocytopenia (HIT), PE or DVT. General patient characteristics
were collected, including but not limited to: Age, gender, height,
weight, body mass index and the amount of day under mechanical
ventilation. Other factors taken into consideration included
patient condition on admission to the intensive care unit; the ICU
length of stay (LOS); units of blood transfused; ICU severity score
including the Acute Physiology and Chronic Health Evaluation
(APACHE) II score [13,14], APACHE III [13,15], Simplified Acute
Physiology Score (SAPS) [16], Multiple Organ Dysfunction score
(MODS) [17]; survival outcomes; and complications (heparin
induced thrombocytopenia [HIT], deep vein thrombosis [18],
and pulmonary embolism [PE], postoperative bleeding, and
vasospasm). Postoperative bleeding, PE and vasospasm were
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evaluated clinically and/or with computed axial tomographic
scan (CT scan). Studies were only ordered after a neurosurgical
evaluation was performed and if there was a high index of
suspicion for intracranial bleeding or an acute change in mental
status. As per institution policy, DVT screening ultrasounds were
not routinely performed, and evaluation of DVT was performed
in setting of high clinical suspicion. Data was compiled, reviewed,
and verified for accuracy by multiple independent reviewers.
Associations between categorical factors were examined using
the chi-square test or Fisher’s exact test, or Pearson correlation
coefficients. Associations between continuous factors (BMI, Age,
APACHE score, APACHE III score, SAPS, MODS) were examined
using the Mann-Whitney U test. LOS in the SICU was calculated
using the product-limit method. Mortality was described using
the Kaplan-Meier method. For all study measures, a p-value
<0.05 indicated statistical significance. Data was collected
and subsequently submitted to the biostatistics department
for analysis. This study was approved by the Northwell Health
System Institutional Review Board.

Results
We identified 1,152 neurosurgical patients, of which 223
emergency neurosurgical patients were included in this study.
100 (44.84%) received no anticoagulation, 123 (55.16%) patients
received SCUFH, of which 88 (71.54%) within 24 h and 35
(28.46%) after 24 h. The mean number of days on SCUFH was
4 ± 5.4. Demographic data are detailed in Table 1. We found
no statistically significant differences in age, ethnicity, sex, and
patient condition upon discharge from SICU between the patients
who did not receive heparin, those who received SCUFH within
24 h, and those who received SCUFH after 24 h.
Table 2 demonstrates the perioperative clinical characteristics. A
statistically significant difference was noted with the admission
MODS score (p-value=0.0009), and APACHE II (p-value=0.045),
of patients receiving SCUFH to those not receiving heparin,
but APACHE III and SAPS on admission were shown to have no
difference in predicting DVT in this study. A statistical difference
was also noted in the median SICU length of stay (LOS) across
the different groups, 4 (2-7) days in patients without DVT
prophylaxis, 5 (3-11) (SCUFH within 24 h) and 7 (3-13) (SCUFH
after 24 h) (Table 2).
Figure 1 shows overall survival of the three groups. No
instances of PE or HIT were observed during the study period.
No postoperative hemorrhages (confirmed by CT scan of the
brain) were observed in any of the neurosurgical patients with
pre-operative diagnoses of subarachnoid hemorrhages (SAH),
intracerebral hemorrhages, or subdural or epidural hemorrhage
(Table 3).
A total of 52 neurologic complications and 123 total complications
were identified (Table 4). We found no statistically significant
difference in the incidence of these complications by group.
Vasospasm (n=9 in no heparin group, n=9 in SCUFH ≤ 24 h, n=8 in
SCUFH>24 h, p=0.091) and cerebrovascular accident (n=5, n=6,
n=5, respectively, p=0.242) were the most common neurologic
This article is available in: http://criticalcare.imedpub.com/archive.php
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Table 1 Demographic data of critically ill neurosurgical patients admitted to the SICU.
Parameter
Sex

Age, (years)

Ethnicity

BMI, kg/m2

Sex, Female n (%)
18-45, year n (%)
46-55, years n (%)
56-65, years n (%)
>65, years n (%)
Total, years Mean (SD)
Caucasian, n (%)
African American, n (%)
Asian, n (%)
Hispanic, n (%)
Other, n (%)
Underweight (<19), n (%)
Ideal, (19-24.9) n (%)
Overweight, (25-29.9) n (%)
Obese, (30-34.9) n (%)
Morbidly Obese, (>35) n (%)
Total, mean (SD)

No heparin
n=100
58 (58.00)
26 (26.00)
14 (14.00)
27 (27.00)
33 (33.00)
57.37 (16.46)
54 (54.00)
7 (7.00)
10 (10.00)
28 (28.00)
1 (1.00)
4 (8.33)
18 (37.50)
18 (37.50)
2 (4.17)
6 (12.50)
26.03 (5.64)

SCUFH ≤ 24 h
n=88
54 (61.36)
19 (21.59)
15 (17.05)
18 (20.45)
36 (40.91)
59.35 (17.20)
58 (65.91)
5 (5.68)
9 (10.23)
14 (15.91)
2 (2.27)
6 (10.00)
30 (50.00)
18 (30.00)
6 (10.00)
0 (0.00)
24.32 (4.61)

SCUFH>24 h
n=35
23 (65.71)
8 (22.86)
7 (20.00)
9 (25.71)
11 (31.43)
57.51 (15.21)
21 (60.00)
2 (5.72)
4 (11.43)
6 (17.14)
2 (5.71)
1 (4.55)
11 (50.00)
5 (22.72)
4 (18.18)
1 (4.55)
26.01 (5.48)

(p)
NS

NS

NS

NS

Total Patients
n=223
88 (39.46)
53 (23.77)
36 (16.14)
54 (24.22)
80 (35.87)
58.17 (16.52)
133 (59.64)
14 (6.28)
23 (10.31)
48 (21.52)
5 (2.24)
11 (8.46)
59 (45.38)
41 (31.54)
12 (9.24)
7 (5.38)
25.24 (5.19)

SCUFH: Subcutaneous Unfractionated Heparin; BMI: Body Mass Index; SD: Standard Deviation; NS: Non-Significant
Table 2 Peri-operative characteristics of the use of SCUFH.

APACHE II, median (Q1-Q3)

No heparin
n=100
8 (4-14)

SCUFH ≤ 24 h
n=88
9 (6.5-14)

SCUFH>24 h
n=35
7 (3-13)

APACHE III, median (Q1-Q3)
Total, median (Q1-Q3)

31 (21-53)
1 (0-2)

34 (23-52)
0 (0-2)

7 (5-11)
0 (0-0)

Score 0, %

43.21

51.14

81.82

Score 1-4, %

49.38

43.18

12.12

Score>4, %

7.4

5.69

6.06

Parameter

MODS

SICU LOS, days median (Q1-Q3)

Mortality, n (%)

NS

38.45 (25.76)

0.0009*

1.22 (1.84)

4 (2-7)

5 (3-11)

7 (3-13)

0.016*

5.67 (5.08)

0 (0-2)

2 (0-3)

2 (0-3)

0.00005*

3.60 (6.36)

Emergency Surgery, n (%)

49 (49.00)

50 (56.82)

22 (62.86)

NS

121 (54.26)

Emergency Room, n (%)

51 (51.00)

38 (43.18)

13 (37.14)

NS

102 (45.74)

Ventilator, days median (Q1-Q3)
Admitting acuity

0.045*

Total Patients
n=223
9.95 (7.07)

(p)

Hospital Mortality

14 (14.00)

15 (17.05)

2 (5.71)

NS

31 (13.90)

30 Days-Mortality

14 (14.00)

15 (17.05)

2 (5.71)

NS

31 (13.90)

SICU Mortality

12 (12.00)

14 (15.91)

2 (5.71)

NS

28 (12.02)

SCUFH: Subcutaneous Unfractionated Heparin; APACHE II: Acute Physiology and Chronic Health Evaluation II; APACHE: Acute Physiology and Chronic
Health Evaluation; SAPS: Simplified Acute Physiology Score; MODS: Multiple Organ Dysfunction Score; SICU: Surgical Intensive Care Unit; LOS: Length
of Stay; Q1: Lower Quartile; Q2: Upper Quartile; SD: Standard Deviation; *: Statistically Significant; NS: Non-Significant

adverse events. Within the cerebrovascular accident subgroup, 1
patient was diagnosed in the group that receives heparin within
24 h with intracerebral hemorrhage upon admission to the SICU.
Postoperative bleeding was observed in only one patient who
received SCUFH within 24 h, and no cases of HIT or VTE were
identified. Among non-neurologic complications, respiratory
complications including ventilator associated pneumonia and
technical issues related to intubation/extubation were most
frequently encountered, occurring in 13 cases of patients without
heparin, 14 in SCUFH ≤ 24 h and 8 in SCUFH>24 h (p=0.394). Cardiac
complications were encountered in 9 patients (n=1, n=4, n=3,
respectively, p=0.07), including cardiac arrhythmias, myocardial
infarction and pulmonary edema. The main contributors of
infectious complications were catheter-related complications.
© Under License of Creative Commons Attribution 3.0 License

Discussion
This study aimed to evaluate the efficacy and safety of SCUFH
in high-risk neurosurgical patients undergoing emergency
surgery. We recently found that the use of SCUFH in the general
neurosurgical population was safe, however, the potential
adverse effects of SCUFH in the high-risk neurosurgery patients
undergoing emergency surgery was largely unknown.
By collecting data on 1,152 patients-days at a single center, this
large retrospective study identified several correlations between
the patient demographics and perioperative characteristics with
the risk of developing bleeding complications.
This trend may be related to the increased comorbidities and
longer LOS seen in the heparin group, as these patients were
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Table 3 Admitting diagnoses/procedures of critically ill neurological patients.

Adrenal crisis

No heparin
n=100
1 (1)

SCUFH ≤ 24 h
n=88
0

SCUFH>24 h
n=35
0

NS

Total Patients
n=223
1

Berry aneurysm

0

1 (1.14)

0

NS

1

Brain abscess

0

0

1 (2.86)

NS

1

Parameter

(p)

Brain carcinoma

5 (5)

2 (2.27)

0

NS

7

Cervical spinal cord compression

2 (2)

1 (1.14)

0

NS

3

Cervical vertebrae fracture

0

1 (1.14)

0

NS

1

Epidural abscess

0

1 (1.14)

0

NS

1

Epidural hematoma

0

1 (1.14)

0

NS

1

Intracerebral hemorrhage

14 (14)

19 (21.59)

6 (17.14)

NS

39

Meningioma

1 (1)

0

0

NS

1

Obstructive hydrocephalus

3 (3)

1 (1.14)

0

NS

4

Paraplegia

0

1 (1.14)

0

NS

1

Subarachnoid hemorrhage

49 (49)

31 (35.23)

24 (75)

0.00046*

104

Subdural hematoma

8 (8)

9 (10.23)

2 (5.71)

NS

19

Others

17 (17)

20 (22.73)

2 (5.71)

NS

49

(): Values are represented in percentage. SCUFH: Subcutaneous Unfractionated Heparin; *: Statistically Significant
Table 4 Post-neurosurgical complications in patients.								

Altered mental state

No heparin
n=100
1 (1)

SCUFH ≤ 24 h
n=88
1 (1.14)

SCUFH>24 h
n=35
0

Bleeding

0

1 (1.14)

Parameter

Neurological
complication

System-based
complications

NS

Total Patients
n=223
2

0

NS

1

(p)

Cerebrovascular accident

5 (5)

6 (6.82)

5 (14.29)

NS

16

Disseminated intravascular coagulation

1 (1)

1 (1.14)

0

NS

2

Heparin-induced thrombocytopenia

0

0

0

NS

0

Paraplegia

0

1 (1.14)

0

NS

1

Thrombophlebitis

0

1 (1.14)

0

NS

1

Vasospasm

9 (9)

9 (10.23)

8 (22.86)

NS

26

Ventriculitis

1 (1)

1 (1.14)

1 (2.86)

NS

3

Venous thromboembolism

0

0

0

NS

0

Total neurological complications

16 (16)

21 (23.86)

14 (40)

0.017*

52

Cardiac

1 (1)

4 (4.55)

3 (8.57)

NS

9

Respiratory

13 (13)

14 (15.91)

8 (22.86)

NS

35

Endocrine

1 (1)

4 (4.55)

1 (2.86)

NS

6

Infectious

3 (3)

6 (6.82)

3 (8.57)

NS

12

Gastrointestinal

1 (1)

1 (1.14)

2 (5.71)

NS

4

Renal

2 (2)

2 (2.27)

1 (2.86)

NS

5

37 (37)

52 (59.09)

32 (91.43)

2.12x10-8*

123

Total Complications

(): Values are represented in percentage. SCUFH: Subcutaneous Unfractionated Heparin; *: Statistically Significant
selected to receive SCUFH whereas the less complex patients did
not.
Evaluation of the data and the Kaplan Meyer curve (Figure 1)
demonstrated a significant p value when comparing no SCUFH
to either arm of the heparin group. Since the non-heparin group
had the worst survival and the heparin groups both had improved
outcomes it could be inferred that the heparin improved
survival. However, clinically is not significant as the data may be

4

confounded. Patients may have been sicker or transfers from the
SICU to the floor delayed. While our cohort was not randomized
into the different treatment regimens, Table 1 shows that these
groups were well matched.
Significant statistical association was noted with the multiple
organ dysfunction score (Table 2). The MODS represents an
attempt to develop reliable, reproducible measure of the
severity of organ dysfunction at the time of ICU admission as
This article is available in: http://criticalcare.imedpub.com/archive.php
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directly cause postoperative hemorrhage. Our findings support
the above claims that the administration of subcutaneous
heparin in the postoperative period is safe, even in patients with
SAH.

Figure 1 SICU Length of stay by groups.
SCUFH: Subcutaneous Unfractionated Heparin; ICU:
Intensive Care Unit

well as quantify subsequent deterioration over the course of the
ICU stay [17]. The MODS was constructed using simple measures
of dysfunction in six organ systems and, therefore, may not
be applicable to the emergency neurosurgical post-operative
population.
We hypothesized that a number of other variables may affect the
likelihood of post-operative VTE, including BMI, advanced age,
anticoagulation medication (Table 1) and admitting diagnoses
and procedures (Table 3). However, none of these hypotheses
were statistically significant. It is possible that this study may be
underpowered to detect these differences.
Abundant data from other meta-analyses and placebo-controlled,
blinded, randomized clinical trials have demonstrated the overall
safety of anticoagulation, as the marginally increased rates of
bleeding with prophylactic doses of low-dose unfractionated
heparin (LDUH), low molecular weight heparin (LMWH), or a
vitamin K antagonist (VKA) are not of clinical significance [19,20].
Several studies support the usage in the neurosurgical population
as well [21-24]. The belief that pharmacologic VTE prophylaxis
should be withheld in any patient at increased risk for bleeding
is largely unsupported by literature, it is yet a practice widely
performed.
Prospective studies of neurosurgical patients who received
perioperative LDUH prophylaxis, has not shown increased
risk of intracranial bleeding. Studies show that perioperative
administration of heparin does not significantly alter bleeding
tendency by any measured parameter [25-30]. This analysis
confirms previous conclusions and supports the usage of
subcutaneous heparin, even in emergency neurosurgical
patients. It is clear that the administration of SCUFH does not

© Under License of Creative Commons Attribution 3.0 License

Our Study has some limitations. First, although data were
prospectively entered into the eICU database, our evaluation
was retrospective. Thus, vulnerable to residual cofounding
which could have explained the lack of association between both
SCUFH groups and mortality. However, those uncaptured factors
would need to have an overwhelming effect in order to hide that
association, which we believe is highly unlikely. Second, given
the lack of post-operative VTE or bleeding events we observed
in Table 4, our study may not have sufficient power to show a
significance association. Our failure to enroll and analyse a larger
number of patients could have led to a type-II error. Because
of limitations in our dataset, we were not able to measure the
median time to the Operating Room since admission. Information
that could have been helpful to better support the emergency
nature from our cohort. Nonetheless, our cohort includes only
the patients who receive neurosurgical intervention within the
first 24 h post-admission. Finally, it should be noted that the
years from 2008 to 2010 reflect a period of changing practice as
regards corticosteroid usage in septic shock
In spite of this limitation, our findings highlight the importance
of the on-going controversies and discussions about the use of
SCUFH in neurosurgical patients after emergency procedures.
In addition, to our knowledge, this study is one of the largest
single center studies on bleeding complications in emergency
neurosurgical patients.

Conclusion
Based on the above analysis, the administration of SCUFH in
emergency neurosurgical patient at 24 h, dosed accordingly
to guidelines for thromboembolism, does not appear to be
associated with increase post operatively bleeding and continues
to be a safe and effective chemoprophylaxis against DVT. Our
study suggests that for post-operative bleeding neurosurgical
patients, the administration of SCUFH should be routinely used
as a VTE prophylactic agent and that it is not an independent risk
factor. Further studies are warranted in a controlled, multicenter,
randomized way to confirm the safety and effectiveness use of
SCUFH in the treatment and prevention against DVT.
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